News | July 01, 2010

New Company Increases Access to Proton Therapy

July 1, 2010 – Two companies this week announced plans to join forces to bring expanded proton therapy access to cancer patients in the United States and worldwide. Proton Therapy USA and CareCapital plc have plans to form Proton Therapy Global Management (PTGM), which will design, develop and manage a global network of proton therapy centers, providing access to this specialized and highly effective treatment to the world’s growing population of cancer patients. Proton therapy is a precise form of radiation treatment that has been very successful in treating a wide range of localized tumors, while leaving healthy tissue mostly intact.

PTGM will develop and manage proton therapy facilities in partnership with some of the world’s most prominent hospitals. To date, letters of intent have been signed to build five centers in the United States and United Kingdom, including two leading academic cancer research centers and a site in central London. The company is in the process of launching a funding entity, Proton Therapy Global Inc., that aims to raise several hundred million dollars for investment in individual proton centers.

The founding PTGM team possesses more than 100 years of combined healthcare experience, having held senior executive positions in leading healthcare organizations and global corporations. The management possesses extensive capital markets experience and expertise in structuring facilities management and real estate partnerships.

In addition, the PTGM team has provided critical leadership to the first facility in the world specifically designed to treat cancer patients with proton therapy, which so far has treated more than 15,000 patients. The team has also built and managed hospitals and medical facility projects on four continents.

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...